Cheng William Hong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4894510/publications.pdf

Version: 2024-02-01

27 papers 903 citations

567281 15 h-index 25 g-index

27 all docs

27 docs citations

times ranked

27

1781 citing authors

#	Article	IF	Citations
1	Repeatability and accuracy of various region-of-interest sampling strategies for hepatic MRI proton density fat fraction quantification. Abdominal Radiology, 2021, 46, 3105-3116.	2.1	5
2	Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs. Bioscience Reports, 2021, 41, .	2.4	28
3	Reader agreement and accuracy of ultrasound features for hepatic steatosis. Abdominal Radiology, 2019, 44, 54-64.	2.1	16
4	Inter-reader agreement of magnetic resonance imaging proton density fat fraction and its longitudinal change in a clinical trial of adults with nonalcoholic steatohepatitis. Abdominal Radiology, 2019, 44, 482-492.	2.1	8
5	Measurement of spleen fat on MRI-proton density fat fraction arises from reconstruction of noise. Abdominal Radiology, 2019, 44, 3295-3303.	2.1	7
6	Longitudinal evolution of CT and MRI LI-RADS v2014 category 1, 2, 3, and 4 observations. European Radiology, 2019, 29, 5073-5081.	4. 5	20
7	Hepatic steatosis and reduction in steatosis following bariatric weight loss surgery differs between segments and lobes. European Radiology, 2019, 29, 2474-2480.	4.5	11
8	Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. Radiology, 2018, 286, 738-763.	7.3	215
9	Crossâ€sectional correlation between hepatic R2* and proton density fat fraction (PDFF) in children with hepatic steatosis. Journal of Magnetic Resonance Imaging, 2018, 47, 418-424.	3.4	19
10	MRI proton density fat fraction is robust across the biologically plausible range of triglyceride spectra in adults with nonalcoholic steatohepatitis. Journal of Magnetic Resonance Imaging, 2018, 47, 995-1002.	3.4	27
11	Optimization of regionâ€ofâ€interest sampling strategies for hepatic MRI proton density fat fraction quantification. Journal of Magnetic Resonance Imaging, 2018, 47, 988-994.	3.4	20
12	Fat Quantification in the Abdomen. Topics in Magnetic Resonance Imaging, 2017, 26, 221-227.	1.2	22
13	PRL3-zumab, a first-in-class humanized antibody for cancer therapy. JCI Insight, 2016, 1, e87607.	5.0	44
14	Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors. CardioVascular and Interventional Radiology, 2016, 39, 409-416.	2.0	4
15	Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 202.e1-202.e7.	1.6	133
16	Imaging and pathology findings after an initial negative MRI-US fusion-guided and 12-core extended sextant prostate biopsy session. Diagnostic and Interventional Radiology, 2014, 20, 234-238.	1.5	11
17	Tapping the treasure of intracellular oncotargets with immunotherapy. FEBS Letters, 2014, 588, 350-355.	2.8	23
18	Prostate Biopsy for the Interventional Radiologist. Journal of Vascular and Interventional Radiology, 2014, 25, 675-684.	0.5	15

#	ARTICLE	IF	CITATIONS
19	Multiparametric prostate MRI and MRI/ultrasound fusion biopsy as tools to follow prostate cancer progression for men on active surveillance Journal of Clinical Oncology, 2014, 32, 63-63.	1.6	2
20	Comparing magnetic resonance imaging/ultrasound-fusion biopsy and systemic 12-core transrectal ultrasound biopsy for whole gland pathology Journal of Clinical Oncology, 2014, 32, 84-84.	1.6	0
21	Needle Slippage From Needle Hub Hardware During Ablation. CardioVascular and Interventional Radiology, 2013, 36, 1436-1437.	2.0	O
22	Integrated laser-guided CT biopsy. Clinical Imaging, 2013, 37, 1135-1137.	1.5	9
23	Can Magnetic Resonance-Ultrasound Fusion Biopsy Improve Cancer Detection in Enlarged Prostates?. Journal of Urology, 2013, 190, 2020-2025.	0.4	73
24	Oncogenic roles of <scp>PRL</scp> â€3 in <scp>FLT</scp> 3â€ <scp>ITD</scp> induced acute myeloid leukaemia. EMBO Molecular Medicine, 2013, 5, 1351-1366.	6.9	44
25	Awaiting a New Era of Cancer Immunotherapy. Cancer Research, 2012, 72, 3715-3719.	0.9	28
26	Engineering the First Chimeric Antibody in Targeting Intracellular PRL-3 Oncoprotein for Cancer Therapy in Mice. Oncotarget, 2012, 3, 158-171.	1.8	42
27	Targeting Intracellular Oncoproteins with Antibody Therapy or Vaccination. Science Translational Medicine, 2011, 3, 99ra85.	12.4	77